Rakai (mass STI treatment) | Masaka A (IEC alone) | Masaka B (IEC plus syndromic management) | Mwanza (syndromic management) | |
---|---|---|---|---|
Keys: ↔ = no change; ↓ = reduction; NA = not available; NS = not significant | ||||
R2, R3 = round (of mass treatment) number 2 and number 3. | ||||
*High titre syphilis defined as TPHA+/RPR titre ⩾1:8 in Mwanza and Masaka, and TPHA+/TRUST titre ⩾1:4 in Rakai. | ||||
TPHA = Treponema pallidum haemagglutination assay; RPR = rapid plasma reagin; TRUST = toluidine red unheated serum test. | ||||
HIV serology (incidence) | ↔ | ↔ | ↔ | ↓ 38% |
Syphilis serology | ↓ 35% at R2 (NS) | ↔ | ↓ 48% | ↓ 31% (NS) |
(TPHA+) (incidence) | ↔ at R3 | |||
High titre syphilis | ↓ 36% at R2 | ↔ | ↓ 42% | ↓ 29% |
serology* (prevalence) | ↓ 20% at R3 | |||
HSV-2 serology (incidence) | NA | ↓ 35% | ↔ | NA |
N gonorrhoeae (prevalence) | ↔ | ↔ | ↓ 72% | ↔ |
C trachomatis (prevalence) | ↔ | ↔ | ↔ | ↔ |
Symptomatic male urethritis (prevalence) | NA | NA | NA | ↓ 49% (borderline) |
T vaginalis in females (prevalence) | ↓ 42% at R2 | NA | NA | ↔ |
↓ 41% at R3 |